News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2017
-
Dec 26, 2017
The Launch of Chugai’s New Corporate Advertisement
“For a tomorrow only possible through biotechnology”
[PDF 314KB] -
Dec 21, 2017
EU Follows US and Approves Chugai’s ALK Inhibitor "Alecensa®" as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer
[PDF 121KB] -
Dec 18, 2017
Launch of the Photodynamic Diagnostic Agent "ALAGLIO® Divided Granules 1.5g"
[PDF 56KB] -
Dec 12, 2017
Notice on Change of Chief Executive Officer
[PDF 30KB] -
Dec 11, 2017
“Atezolizumab” plus “Avastin” Significantly Improves Progression Free Survival Compared with Sunitinib in PD-L1 Positive Patients for the First-line Treatment of Advanced Renal Cell Carcinoma in the IMmotion151 Study
[PDF 140KB] -
Dec 07, 2017
Chugai’s Emicizumab Every Four Weeks Showed Positive Interim Results
in Phase III Study
[PDF 234KB] -
Dec 01, 2017
Organizational and Personnel Changes
[PDF 178KB] -
Nov 29, 2017
TWOCELLS and Chugai Announce Performing Surgery of the First Patient in Phase III Trial for “gMSC®1,” a Regenerative Cellular Medicine for Chondrogenesis in the Knee
[PDF 57KB] -
Nov 21, 2017
Immune Checkpoint Inhibitor “Atezolizumab” Significantly Improves Progression Free Survival in Patients with Non-Small Cell Lung Cancer Compared with Chemotherapy in the IMpower150 Study
[PDF 121KB] -
Nov 20, 2017
Chugai’s Bispecific Antibody Emicizumab
Meets Primary Endpoint in Phase III Study
- emicizumab prophylaxis shown to reduce bleeding in patients without inhibitors - [PDF 123KB] -
Nov 17, 2017
Chugai’s HEMLIBRA® Receives the World’s First Regulatory Approval from FDA for Hemophilia A with Inhibitors
[PDF 118KB] -
Nov 14, 2017
Marketing and Manufacturing Right Transfer of 13 Long-Term Listed Products
from Chugai to Taiyo Pharma
[PDF 119KB] -
Nov 14, 2017
Concerning Today's Certain Media Report
[PDF 50KB] -
Nov 08, 2017
Chugai's ALK Inhibitor "Alecensa®" Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US
[PDF 74KB] -
Nov 07, 2017
"AYA’s Life," a Website for Young Cancer Patients and Their Families, Undergoes Major Upgrade
- For the Future of Generation AYA Living with Cancer - [PDF 176KB] -
Nov 06, 2017
Eldecalcitol, an Active Vitamin D3 Derivative, Increases Bone Mineral Density of Osteoporosis Patients in Chinese Phase III Study
[PDF 107KB] -
Nov 02, 2017
New Data of Emicizumab Presented
at The American Society of Hematology 2017
[PDF 101KB] -
Oct 25, 2017
Anti-Cancer Agent "Perjeta®"
Filed for Additional Indication of Adjuvant Therapy for HER2-Positive Early Breast Cancer
[PDF 113KB] -
Oct 19, 2017
F. Hoffmann-La Roche Announces Third Quarter Sales 2017
[PDF 151KB] -
Oct 05, 2017
Chugai's Bispecific Antibody "ERY974"
Results of Preclinical Study Published in Science Translational Medicine
- Chugai's Research Findings Adopted by World-Class Academic Journal - [PDF 113KB] -
Sep 27, 2017
"ALAGLIO® Divided Granules 1.5g," a Photodynamic Diagnostic Agent
Obtained Manufacture and Marketing Approval
[PDF 161KB] -
Sep 11, 2017
Contribution of Para-transit Vehicles to Welfare Services
[PDF 195KB] -
Sep 08, 2017
Filing of Lawsuit on Patent Infringement Concerning Herceptin® Injection, and a Petition for Provisional Disposition Order
[PDF 67KB] -
Aug 25, 2017
Approval of Actemra®for Additional Indications of
Takayasu Arteritis and Giant Cell Arteritis,
Both are Designated Intractable Diseases
[PDF 71KB] -
Aug 24, 2017
Chugai’s Emicizumab Receives Priority Review Designation by FDA
for Hemophilia A with Inhibitors
[PDF 113KB] -
Aug 23, 2017
New Drug Application Filed for Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab
[PDF 40KB] -
Aug 10, 2017
Announcement of a Commencement of Arbitration against Chugai
[PDF 45KB] -
Jul 31, 2017
Chugai and National Cancer Center Japan
Enter into Joint Research Agreement
Chugai Joins “MASTER KEY Project”, an industry-academia joint project promoting research and development on rare cancers and genomic medicine
[PDF 104KB] -
Jul 27, 2017
Judgment Rendered on the Suit for Damages with Regard to the Process Patent Infringement for OXAROL® Ointment
[PDF 95KB] -
Jul 27, 2017
Personnel Changes
[PDF 128KB] -
Jul 27, 2017
F. Hoffmann-La Roche Announces Half Year Results 2017
[PDF 81KB] -
Jul 21, 2017
Chugai Files a New Drug Application for Its Bispecific Monoclonal Antibody “Emicizumab” for the Treatment of Congenital Factor VIII Deficiency (Hemophilia A) with Factor VIII Inhibitors
[PDF 60KB] -
Jul 10, 2017
Chugai’s Bispecific Antibody “Emicizumab”
Global Phase III Data in Patients with Haemophilia A with Inhibitors
Published in The New England Journal of Medicine Online
[PDF 113KB] -
Jun 29, 2017
Appointment of Chugai’s Deputy Chairman Motoo Ueno as
President of Business Ethics Research Center (BERC)
[PDF 111KB] -
Jun 27, 2017
Chugai to Sponsor “2017 Wheelchair Softball Tournament in Tokyo”
[PDF 300KB] -
Jun 26, 2017
Approval of Additional Dosage for “Actemra® Subcutaneous Injection” Reducing Dose Interval to One Week in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose
[PDF 63KB] -
Jun 26, 2017
Chugai’s Bispecific Antibody Emicizumab to Present
Results of Two Pivotal Phase lll Studies at ISTH
[PDF 195KB] -
Jun 06, 2017
Data of Chugai's Alecensa® Presented at the American Society of Clinical Oncology on Global Phase III ALEX Study
- Alecensa® Demonstrates Statistically Significant Improvement in PFS and Reducing Risk of CNS Progression or Death - [PDF 124KB] -
Jun 01, 2017
Contribution of Funds to the Second Phase of
the Global Health Innovative Technology Fund (GHIT Fund)
[PDF 69KB] -
May 11, 2017
Results of the J-ALEX Study for Chugai's Alecensa® are Published in “The Lancet” Online
[PDF 165KB] -
May 11, 2017
Announcement of a Lawsuit Filed against Chugai
[PDF 22KB] -
May 10, 2017
Chugai Enters into a License Agreement for Emicizumab with JW Pharmaceutical
[PDF 161KB] -
May 10, 2017
Update on Phase III study of Immune Checkpoint Inhibitor
“Atezolizumab” in Patients with Locally Advanced or
Metastatic Urotherial Carcinoma
[PDF 161KB] -
Apr 27, 2017
F. Hoffmann-La Roche Announces First Quarter Sales 2017
[PDF 77KB] -
Apr 25, 2017
Notice regarding Cancellation of Treasury Stocks
[PDF 117KB] -
Apr 10, 2017
Chugai's Alecensa® Met Its Primary Endpoint in the ALEX Study
- Following the Japanese P3 Study, Alecensa Demonstrated Statistically Significant Improvement in PFS in a Global P3 Head to Head Study with Crizotinib - [PDF 119KB] -
Apr 05, 2017
Establishment of “AYA’s Life,” a Website for Cancer Patients in Generation AYA and Their Families
- For the Future of Generation AYA Living with Cancer - [PDF 102KB] -
Apr 04, 2017
A First Approach in the Japanese Pharmaceutical Industry
Starting a Trial of a Drug Adherence Support App
Using Multidisciplinary SNS for Outpatient Cancer Treatment
--Providing a New Solution for Side Effect Management--
[PDF 720KB] -
Mar 30, 2017
Chugai - A*STAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund
[PDF 74KB] -
Mar 24, 2017
The Supreme Court Rendered Favorable Judgment on Patent-Infringement Lawsuit Regarding OXAROL® Ointment
[PDF 93KB] -
Mar 24, 2017
Anti-Influenza Drug, “Tamiflu® Dry Syrup 3%,” Obtained Approval for Additional Dosage and Administration for Newborns and Infants
[PDF 70KB] -
Mar 24, 2017
Approval of Antiviral Drug, COPEGUS® for Additional Indication for Improvement of Viraemia in Patients with neither Serogroup 1 nor 2 Chronic Hepatitis C or Compensated Cirrhosis Related to Hepatitis C
[PDF 80KB] -
Mar 23, 2017
Chugai Selected as a “Nadeshiko Brand” for the Third Consecutive Year
-- Active Diversity and Inclusion Measures Continue to be Highly Appreciated by Outside Agencies -- [PDF 143KB] -
Mar 23, 2017
Notice regarding Issuance of New Shares as Restricted Stock Compensation Plan
[PDF 77KB] -
Mar 13, 2017
SBI Pharma and Chugai Enter an Agreement of
Exclusive Marketing Rights for “ALAGLIO® Granule 1.5g” in Japan
[PDF 59KB] -
Mar 02, 2017
Chugai’s Anti-IL-31 Receptor A Humanized Monoclonal Antibody “nemolizumab (CIM331)”
Global Phase II Study Data Published in The New England Journal of Medicine Online
[PDF 153KB] -
Feb 27, 2017
Chugai’s ALK Inhibitor “Alecensa®” Approved in Taiwan
[PDF 83KB] -
Feb 21, 2017
Chugai’s ALK Inhibitor “Alecensa®” Approved in the EU
- Alecensa is Available Now in Japan, the United States and Europe - [PDF 130KB] -
Feb 17, 2017
New Drug Application Filed for Immune Checkpoint Inhibitor, Atezolizumab
- First Application as anti PD-L1 Antibody for the Treatment of Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer in Japan - [PDF 128KB] -
Feb 01, 2017
Organizational and Personnel Changes
[PDF 292KB] -
Feb 01, 2017
Notice regarding introduction of a Restricted Stock Compensation Plan
and a change of compensation amount for Directors
[PDF 121KB] -
Feb 01, 2017
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2016
[PDF 101KB] -
Jan 27, 2017
Chugai Wins the Grand Prize for the Second Consecutive Year in the 19th NIKKEI Annual Report Awards
[PDF 170KB] -
Jan 25, 2017
Personnel Changes
[PDF 129KB] -
Jan 25, 2017
Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services
- Reorganization toward Implementation of Area-based Strategies for Each Prefecture - [PDF 243KB] -
Jan 18, 2017
Chugai to Join Global Initiative for Addressing Rise of Non-Communicable Diseases in Low and Lower-Middle Income Countries
[PDF 71KB] -
Jan 16, 2017
Transfer of Rights to Insomnia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
[PDF 145KB]
